M&A / Jazz’s $7.2 Billion GW Pharma Deal: A Major Boost for Cannabinoid Research
The first day of March 2013 also marked a first for GW Pharmaceuticals. On that day, the British biopharmaceutical…
Address: Chiltern Place, Chalfont Park
Gerrards Cross
Buckinghamshire SL9 0BG
,United Kingdom
Tel: +44 17 53 893600
Web: http://www.daiichi-sankyo.co.uk/
Daiichi Sankyo is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets.
The company does business in nearly 60 countries around the world, including 12 European countries. With net sales of nearly €8.55 billion in fiscal year 2010 (as of 31 March 2011), Daiichi Sankyo is one of the world’s 20 leading pharmaceutical companies.
While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia and bacterial infections, Daiichi Sankyo is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular metabolic therapies.
The first day of March 2013 also marked a first for GW Pharmaceuticals. On that day, the British biopharmaceutical…
When the European Medicines Agency (EMA) relocated from London to Amsterdam after the UK announced its decision to…
The signing of an agreement on the terms of a future trade relationship between Japan and the UK has been welcomed…
US Merck (MSD globally) is following through on a 2017 commitment to invest in a new early research hub in central…
Jameel Zayed of Leyton, the UK’s leading innovation funding consultancy, highlights the British pharmaceutical…
Below we highlight some recent developments in pharma and healthcare in the UK, including drug shortages in British…
The world’s two leading vaccine producers, GSK of the UK and France’s Sanofi, last week announced that they are…
With Brexit now confirmed, the UK government has been playing up the country’s scientific credentials. The aim is…
Friday January 31 2020 was officially dubbed “Brexit Day” as the UK finally left the EU, following British…
Although biotech financing in the UK took a hit last year in large part thanks to uncertainty around Brexit, 2019…
GW Pharmaceuticals reports that sales of its CBD drug Epidiolex more than doubled in the second quarter of 2019,…
Formed in 2015, listed UK start-up Amryt targets rare diseases with high unmet medical need. With one commercial…